FDA proposes new market pathway for devices touting safety innovations

FDA
Acceptable devices include those designed to reduce known risks, such as serious adverse events, device failures, use-related hazards or user errors. (Andrew Harnik, Associated Press)

The FDA outlined a new pathway for the expedited approval of medical devices, diagnostics and certain combination products that aim to improve upon the safety of those currently on the market.

The agency modeled the voluntary regulatory process after its selective Breakthrough Devices Program, but with the goal of recognizing and rewarding innovation in areas that might not make the cut.

While the breakthrough program focuses on life-threatening diseases and unmet medical needs, the Safer Technologies Program—or “STeP”—will be designed for less-severe conditions but where previously approved products may carry serious treatment risks nonetheless.

Webinar

CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

The new program will include similar benefits, such as priority review and increased communication with FDA staff during the development process, as resources permit. It will cover devices and device-led combination products undergoing premarket approval, de novo or 510(k) clearance reviews.

“We will do this without changing our statutory standards, data requirements or quality of review,” the FDA’s device center director, Jeff Shuren, said in a statement. “Safety and innovation are both important priorities for the agency.”

RELATED: FDA sets novel device approval record for 2018, outlines new criteria for 510(k) clearances

In a draft guidance describing the program, the FDA said it believes efforts to improve device safety will lead to improvements in overall clinical benefits, as well as fewer adverse events.

Devices that will be accepted under the program include those with “substantial safety innovations” designed to reduce known risks—including serious adverse events, device failures, use-related hazards or user errors. This also includes devices designed to improve the safety of other medical devices or interventions.

While the FDA intends to apply many of the processes used in the breakthrough program to products expedited under STeP, should resources become strained, the agency said it would prioritize the Breakthrough Devices Program due to its mandates under federal law.

RELATED: FDA shutters its alternative device report database, disclosing 20 years of safety data

Separately, the FDA published four sets of performance criteria, built around specific device types, that manufacturers can use in lieu of a predicate device during a 510(k) submission.

They include: conventional foley catheters, skin-based electrodes for reporting purposes, spinal plating systems, and orthopedic non-spinal metallic bone screws and washers.

“This new option for 510(k) clearance of certain well-understood device types will allow manufacturers to use objective performance criteria—established or recognized by the FDA—to demonstrate substantial equivalence of their new products or superior performance to those already legally on the market,” Shuren said.

“For example, if a manufacturer wants to market a new spinal plating system that falls within the scope of the guidance, with this new pathway, they would submit a 510(k) demonstrating that the safety and performance characteristics of their device are consistent with the new FDA-identified criteria,” he added. “They would not need to provide a side-by-side performance assessment with a predicate device.”

In some cases, previously approved, predicate devices may be older, and not contain modern technology or features, the FDA said.

“This new approach may also drive greater market competition to develop safer, more effective devices by providing the opportunity to demonstrate superior performance to the FDA-established benchmarks,” Shuren said.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.